A Phase III, Open-label Study of MT-6548 in Peritoneal Dialysis Subjects With Anemia Associated With Chronic Kidney Disease in Japan

Trial Profile

A Phase III, Open-label Study of MT-6548 in Peritoneal Dialysis Subjects With Anemia Associated With Chronic Kidney Disease in Japan

Recruiting
Phase of Trial: Phase III

Latest Information Update: 11 Apr 2018

At a glance

  • Drugs Vadadustat (Primary)
  • Indications Anaemia
  • Focus Therapeutic Use
  • Sponsors Mitsubishi Tanabe Pharma Corporation
  • Most Recent Events

    • 12 Feb 2018 According to an Akebia Therapeutics media release, data read-out expected in 2019.
    • 09 Jan 2018 New trial record
    • 04 Jan 2018 This trial is expected to begin in 2018, according to an Akebia Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top